To include your compound in the COVID-19 Resource Center, submit it here.

Tracon reports Phase I/II data for TRC105 in HCC

Tracon Pharmaceuticals Inc. (NASDAQ:TCON) reported data from 24 evaluable patients with advanced hepatocellular carcinoma (HCC) in an NCI-led Phase I/II trial showing that

Read the full 231 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE